PIPS Key Facts
Active Substance |
Active Substance:
|
Invented Name
|
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Selara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
- Stelara
|
PIP Number |
MHRA-101723-PIP01-24-M01 (update) |
Pharmaceutical form(s)
|
Pharmaceutical form(s):
- Solution for injection
Concentrate for solution for infusion
|
Therapeutic area
|
Therapeutic area:
- Immunology -Rheumatology-Transplantation
|
Conditions / Indications
|
Conditions / Indications:
- Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis).
|
Route(s) of administration
|
- intravenous
- Subcutaneous use
|
PIP applicant
|
|
Decision Type
|
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
|
Compliance Check
|
|
Compliance Check Decision Date
|
|
Compliance Check Procedure Number
|
|